AI assistant
N4 PHARMA PLC — Remuneration Information 2017
Dec 22, 2017
7804_dirs_2017-12-22_691fd7b9-5e79-40fb-82e8-e3ad60397aec.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 2118A
Evgen Pharma PLC
22 December 2017
For immediate release 22 December 2017
Evgen Pharma plc
("Evgen" or the "Company")
Grant of Options
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 21 December 2017, certain employees of the Company including the following Persons Discharging Managerial Responsibility ("PDMR") were granted nil cost options over a total of 807,234 ordinary shares in the Company exercisable, subject to the option vesting, for a period of up to ten years from the date of grant under the Evgen Pharma plc Long Term Incentive Plan ("LTIP").
| PDMR | Position | Options granted |
| Dr Stephen Franklin | Chief Executive Officer | 437,760 |
| Richard Moulson | Chief Financial Officer | 289,352 |
| David Chadwick | Head of Clinical Operations | 69,444 |
The number of nil cost options awarded has been calculated by reference to the three month weighted average share price to 24 November 2017.
These nil cost options are subject to the rules of the LTIP and will vest based on share price performance between the date of grant and the third anniversary of grant.
Enquiries:
| Evgen Pharma plc | c/o +44 (0) 20 7466 5000 |
| Dr Stephen Franklin, CEO Richard Moulson, CFO |
|
| www.evgen.com | |
| Northland Capital Partners Limited | +44 (0) 20 3861 6625 |
| Matthew Johnson, Gerry Beaney (Corporate Finance) | |
| John Howes, Rob Rees (Corporate Broking) | |
| Buchanan | +44 (0) 20 7466 5000 |
| Mark Court, Sophie Cowles, Stephanie Watson | |
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Steve Franklin | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Executive | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Evgen Pharma Plc | |
| b) | Legal Entity Identifier | 213800NO3E6TSTQO8K20 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Options over ordinary shares of 0.25 pence each GB00BSWYN304 |
|
| b) | Nature of the transaction | Grant of options | |
| c) | Currency | GBP | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| nil | 437,760 | ||
| e) | Aggregated information - Aggregated volume - Price - Aggregated total |
||
| f) | Date of the transaction | 21 December 2017 | |
| g) | Place of the transaction | London Stock Exchange, AIM |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Richard Moulson | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Financial Officer | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Evgen Pharma plc | |
| b) | Legal Entity Identifier | 213800NO3E6TSTQO8K20 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Options over ordinary shares of 0.25 pence each GB00BSWYN304 |
|
| b) | Nature of the transaction | Grant of options | |
| c) | Currency | GBP | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| nil | 289,352 | ||
| e) | Aggregated information - Aggregated volume - Price - Aggregated total |
||
| f) | Date of the transaction | 21 December 2017 | |
| g) | Place of the transaction | London Stock Exchange, AIM |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | David Chadwick | |
| 2 | Reason for the notification | ||
| a) | Position/status | Head of Clinical Operations | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Evgen Pharma plc | |
| b) | Legal Entity Identifier | 213800NO3E6TSTQO8K20 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Options over ordinary shares of 0.25 pence each GB00BSWYN304 |
|
| b) | Nature of the transaction | Grant of options | |
| c) | Currency | GBP | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| nil | 69,444 | ||
| e) | Aggregated information - Aggregated volume - Price - Aggregated total |
||
| f) | Date of the transaction | 21 December 2017 | |
| g) | Place of the transaction | London Stock Exchange, AIM |
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHOKBDKKBDDABB